Suppr超能文献

混合胍基/烷基亚胺基/叠氮钨(VI)配合物:合成与结构表征

Mixed guanidinato/alkylimido/azido tungsten(VI) complexes: synthesis and structural characterization.

作者信息

Rische Daniel, Baunemann Arne, Winter Manuela, Fischer Roland A

机构信息

Lehrstuhl für anorganische Chemie II, Ruhr-Universität Bochum, Germany.

出版信息

Inorg Chem. 2006 Jan 9;45(1):269-77. doi: 10.1021/ic0512431.

Abstract

A series of structurally characterized new examples of pentacoordinated heteroleptic tungsten(VI)-guanidinates complexes are described. Starting out from [WCl(2)(Nt-Bu)(2)py(2)] (1) (py = pyridine) and the guanidinato transfer reagents (TMEDA)Li[(Ni-Pr)(2)CNi-Pr(2)] (2a) (TMEDA = N,N,N',N'-tetramethylethylendiamine) and Li(NC(NMe(2))(2)) (2b), the title compounds [WCl(Nt-Bu)(2)[(Ni-Pr)(2)CNi-Pr(2)]] (3) and [W(Nt-Bu)(2)Cl{NC(NMe(2))(2)]](2) (6) were selectively formed by the elimination of one mole equivalent of lithium chloride. The isopropyl-substituted guanidinato ligand [(Ni-Pr)(2)CNi-Pr(2)} of monomeric 3 is N(1),N(3)-bonded to the tungsten center. The introduction of the sterically less-demanding tetramethyl guanidinato ligand [NC(NMe(2))(2)] expectedly leads to dimeric 6 exhibiting a planar W(2)N(2) ring with the guanidinato group bridging the two tungsten centers via the deprotonated imino N-atom. The remaining chloro ligand of 3 is labile and can be substituted by sterically less-crowded groups such as dimethylamido or azido that yield the presumably monomeric compounds 4 and 5, respectively. A similar treatment of 6 with sodium azide yields the dimeric azido derivative 7. Reacting [WCl(2)(Nt-Bu)(2)py(2)] directly with an excess of sodium azide leads to the dimeric bis-azide species [W(Nt-Bu)(2)(N(3))(mu(2)-N(3))py]. The new compounds were fully characterized by single-crystal X-ray diffractometry (except 2, 4, and 5), NMR, IR, and mass-spectroscopy as well as elemental analysis. Compound 5, [W(N(3))(Nt-Bu)(2)[(Ni-Pr)(2)CNi-Pr(2)]], can be sublimed at 80 degrees C, 1 Pa.

摘要

描述了一系列结构特征明确的五配位杂配钨(VI)-胍配合物的新实例。从[WCl₂(Nt-Bu)₂py₂](1)(py = 吡啶)和胍基转移试剂(TMEDA)Li[(Ni-Pr)₂CNi-Pr₂](2a)(TMEDA = N,N,N',N'-四甲基乙二胺)以及[Li(NC(NMe₂)₂)]ₓ(2b)出发,通过消除一摩尔当量的氯化锂,选择性地形成了标题化合物[WCl(Nt-Bu)₂[(Ni-Pr)₂CNi-Pr₂]](3)和[W(Nt-Bu)₂Cl{NC(NMe₂)₂}]₂(6)。单体3的异丙基取代胍基配体[(Ni-Pr)₂CNi-Pr₂]通过N(1),N(3)键合到钨中心。引入空间需求较小的四甲基胍基配体[NC(NMe₂)₂]预期会导致二聚体6呈现平面W₂N₂环,其中胍基通过去质子化的亚氨基N原子桥连两个钨中心。3中剩余的氯配体不稳定,可以被空间拥挤程度较小的基团如二甲基氨基或叠氮基取代,分别生成可能的单体化合物4和5。用叠氮化钠对6进行类似处理得到二聚体叠氮衍生物7。[WCl₂(Nt-Bu)₂py₂]直接与过量的叠氮化钠反应生成二聚体双叠氮物种[[W(Nt-Bu)₂(N₃)(μ₂-N₃)py]₂]。通过单晶X射线衍射(2、4和5除外)、核磁共振、红外光谱、质谱以及元素分析对新化合物进行了全面表征。化合物5,[W(N₃)(Nt-Bu)₂[(Ni-Pr)₂CNi-Pr₂]],可以在80℃、1 Pa下升华。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验